Publications by authors named "A Ruggenini Moiraghi"
Background And Objectives: The risk-to-benefit ratio of transopercular awake resection for recurrent insular diffuse gliomas is poorly studied. We assessed feasibility, safety, and efficacy of awake surgical resection of recurrent insular diffuse gliomas in patients with previous treatments (resection and/or radiotherapy and/or chemotherapy and/or combination).
Methods: Observational, retrospective, single-institution cohort analysis (2010-2023) of 123 consecutive adult patients operated on for an insular diffuse glioma (2021 World Health Organization classification) under awake conditions.
Injury of the internal carotid artery (ICA), anterior cerebral artery (ACA), and middle cerebral artery (MCA) are rare but devastating complications during microsurgery of the anterior and middle cranial skull base. We systematically reviewed the current knowledge on ICA, ACA, and MCA injury during skull base microsurgery and performed a multicentric data collection to refine their management. A systematic review of ICA, ACA, and MCA injuries during direct microsurgical approaches to the anterior and middle cranial skull base was performed, using PRISMA-IPD guidelines and using a multicentric case collection.
View Article and Find Full Text PDFArticle Synopsis
- A study examined the effectiveness of a watch-and-wait strategy versus standard postoperative treatment in patients with grade 3 gliomas after surgery, focusing on -mutant cases.
- An analysis of 106 patients over 12 years showed that those in the watch-and-wait group had better pre-surgery health metrics but similar long-term survival rates compared to those receiving adjuvant oncological treatment.
- The findings suggest that patients with selected grade 3 gliomas who undergo complete tumor removal can safely opt for a watch-and-wait approach without negatively impacting their survival outcomes.
Article Synopsis
- The study focused on glioblastoma, IDH-wildtype, examining survival rates and factors influencing long-term survival in patients diagnosed between 2000 and 2021.
- The median overall survival was found to be 11.2 months, with only 17.6% of patients surviving 2 years and a mere 2.2% surviving 5 years.
- Two key factors for improved survival included receiving standard combined chemoradiotherapy and having a methylated O6-methylguanine-DNA methyltransferase promoter, along with age and specific imaging characteristics at diagnosis.